PMID- 37195125
OWN - NLM
STAT- MEDLINE
DCOM- 20230530
LR  - 20230530
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 23
IP  - 5
DP  - 2023 May
TI  - Anti-IL17 treatment in childhood chronic rheumatic diseases.
PG  - 429-441
LID - 10.1080/14712598.2023.2215923 [doi]
AB  - INTRODUCTION: Interleukin-17 (IL-17) is a family of cytokines that plays a key 
      role in several rheumatic diseases in both adults and children. In the last few 
      years, several drugs targeting IL-17 have been developed. AREAS COVERED: We 
      present a review on the current state of the art regarding the use of anti-IL17 
      in childhood chronic rheumatic diseases. To date, the available evidence is 
      limited and mainly focuses on juvenile idiopathic arthritis (JIA) and a specific 
      autoinflammatory disease called deficiency of IL-36 receptor antagonist (DITRA). 
      Recently, a randomized controlled trial resulted in the approval of secukinumab 
      (an anti-IL17 monoclonal antibody) for JIA, due to its demonstrated efficacy and 
      safety. Promising and potential uses of anti-IL17 in Behcet's syndrome and 
      synovitis acne pustulosis hyperostosis osteitis (SAPHO) syndrome have also been 
      described. EXPERT OPINION: Increasing knowledge about the pathogenetic mechanisms 
      underlying rheumatic diseases is leading to an improvement in the care of several 
      chronic autoimmune diseases. In this scenario, anti-IL17 therapies (such as 
      secukinumab and ixekizumab) might be an optimal choice. Recent data on the use of 
      secukinumab in juvenile spondyloarthropathies can be a starting point for future 
      treatment strategies in other pediatric rheumatic diseases, such as Behcet's 
      syndrome and the chronic non-bacterial osteomyelitis disease spectrum, 
      particularly SAPHO syndrome.
FAU - Maniscalco, Valerio
AU  - Maniscalco V
AD  - Department of Health Sciences, University of Florence, Firenze, Italy.
FAU - Maccora, Ilaria
AU  - Maccora I
AUID- ORCID: 0000-0001-6418-3254
AD  - Rheumatology Unit, ERN-ReCONNET center, Meyer Children Hospital IRCCS, Firenze, 
      Italy.
AD  - NEUROFARBA Department, University of Florence, Firenze, Italy.
FAU - Girodo, Flavio
AU  - Girodo F
AD  - Department of Health Sciences, University of Florence, Firenze, Italy.
FAU - Tomaselli, Marta
AU  - Tomaselli M
AD  - Department of Health Sciences, University of Florence, Firenze, Italy.
FAU - Priolo, Gaia
AU  - Priolo G
AD  - Department of Health Sciences, University of Florence, Firenze, Italy.
FAU - Marrani, Edoardo
AU  - Marrani E
AD  - Rheumatology Unit, ERN-ReCONNET center, Meyer Children Hospital IRCCS, Firenze, 
      Italy.
FAU - Mastrolia, Maria Vincenza
AU  - Mastrolia MV
AD  - Rheumatology Unit, ERN-ReCONNET center, Meyer Children Hospital IRCCS, Firenze, 
      Italy.
FAU - Pagnini, Ilaria
AU  - Pagnini I
AD  - Rheumatology Unit, ERN-ReCONNET center, Meyer Children Hospital IRCCS, Firenze, 
      Italy.
FAU - Simonini, Gabriele
AU  - Simonini G
AD  - Rheumatology Unit, ERN-ReCONNET center, Meyer Children Hospital IRCCS, Firenze, 
      Italy.
AD  - NEUROFARBA Department, University of Florence, Firenze, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230519
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Interleukin-17)
RN  - 0 (Cytokines)
SB  - IM
MH  - Adult
MH  - Child
MH  - Humans
MH  - Interleukin-17
MH  - *Behcet Syndrome
MH  - *Psoriasis/drug therapy
MH  - *Rheumatic Diseases/drug therapy
MH  - Cytokines/therapeutic use
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Behcet's syndrome
OT  - IL17 inhibitors
OT  - SAPHO syndrome
OT  - biologic therapy
OT  - children
OT  - ixekizumab
OT  - juvenile idiopathic arthritis
OT  - noninfectious uveitis
OT  - secukinumab
EDAT- 2023/05/17 13:10
MHDA- 2023/05/30 06:42
CRDT- 2023/05/17 09:34
PHST- 2023/05/30 06:42 [medline]
PHST- 2023/05/17 13:10 [pubmed]
PHST- 2023/05/17 09:34 [entrez]
AID - 10.1080/14712598.2023.2215923 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2023 May;23(5):429-441. doi: 
      10.1080/14712598.2023.2215923. Epub 2023 May 19.